Patients with anti-MDA5 antibodies experience particularly aggressive, rapidly progressive ILD and shorter survival, whereas those with anti-TIF1-γ antibodies require vigilant malignancy surveillance. This evidence concerns the gene TRIM24 and interstitial lung disease.